Alchemab Therapeutics
Dr. Galson is experienced in the development and application of novel technologies in the biotechnology sector. Previously he was the Bioinformatics lead at Kymab Ltd, where his group developed the IntelliSelect® antibody discovery software platform. Dr. Galson is also one of the pioneers of immune receptor repertoire sequencing, serving as a member of the AIRR community, and authoring numerous key publications in the area. He has worked at The Oxford Vaccine Group, GSK Vaccines, and University of Zürich, applying this approach to further understand basic immunology, as well as in support of vaccine development, diagnostics, and antibody drug discovery.
Dr. Galson holds a BA in Biological Sciences (First Class) and a PhD in Medical Sciences, both from the University of Oxford.
This person is not in any offices
Alchemab Therapeutics
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.